First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: japanese subgroup of keynote-048

HIGHLIGHTS

• who: Shunji Takahashi from the PD-, u00b7 Japan have published the research work: First-line pembrolizumabu2009u00b1u2009chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048, in the Journal: (JOURNAL) of 25/02/2019
• what: Background Here the authors report the results of the Japanese subgroup of the phase 3 KEYNOTE-048 study of pembrolizumab alone pembrolizumab plus platinum and 5-fluorouracil (pembrolizumab-chemotherapy) or cetuximab plus platinum and 5-fluorouracil (EXTREME) in previously untreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The authors report the final analysis of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.